Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation

Hamada, Ryota; Oshima, Yasuhiro; Satô, Susumu; Yoshioka, Yumiko; Nankaku, Manabu; Kondo, Tadakazu; Chen‐Yoshikawa, Toyofumi F.; Ikeguchi, Ryosuke; Nakajima, Daisuke; Date, Hiroshi; Matsuda, Shinya

doi:10.1007/s00520-021-06592-0

Cited by 3 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incidence of infections varied between 11-50%, depending on type of infection, with cytomegalovirus and fungal infections being the most common. [95][96][97][98][99][100][101][102][103] Acute cellular rejection occurred in 11-43% of patients and was similar to the incidence in other lung transplant patients. [95][96][97][98][99][100][101] The incidence of haematological relapse and malignancy was low (0-8% and 17%, respectively).…”

Section: Summary Of Evidencementioning

confidence: 96%

“…Nine observational studies (five retrospective cohort studies [95][96][97][98][99], four case series [100][101][102][103]) were identified that looked at lung transplantation outcomes for lung cGvHD-BOS (2-18 BOS patients per study, 76 in total). Overall survival was good, with reported 1-year survival of 78-90% [97][98][99] and 5year survival of 75-80% [96,97].…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Other studies reported overall survival of 50%, 67% and 100% at a median follow-up of 20-24 months. [99][100][101] Moreover, overall survival was similar compared to matched controls [97] and the general lung transplant population [95]. Main causes of death were infection, lung graft failure/chronic lung allograft dysfunction, malignancy, and haematological relapse.…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Main causes of death were infection, lung graft failure/chronic lung allograft dysfunction, malignancy, and haematological relapse. [95][96][97][98][99]101,103] Freedom from chronic lung allograft dysfunction was 51% at five years in a study by Kliman et al [96] and 67-100% in other studies [95,97,[100][101][102], depending on time of post-transplant follow-up. Incidence of infections varied between 11-50%, depending on type of infection, with cytomegalovirus and fungal infections being the most common.…”

Section: Summary Of Evidencementioning

confidence: 99%

See 3 more Smart Citations

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Bos,

Murray,

Marchetti

et al. 2024

Eur Respir J

View full text Add to dashboard Cite

Chronic graft-versus-host disease (cGvHD) is a common complication after allogeneic haematopoietic stem cell transplantation, characterised by a broad disease spectrum that can affect virtually any organ. Although pulmonary cGvHD is a less common manifestation, it is of great concern due to its severity and poor prognosis. Optimal management of patients with pulmonary cGvHD is complicated and no standardised approach is available.The purpose of this joint European Respiratory Society and European Society for Blood and Marrow Transplantation Task Force was to develop evidence-based recommendations regarding the treatment of pulmonary cGvHD phenotype bronchiolitis obliterans syndrome in adults. A multidisciplinary group representing specialists in haematology, respiratory medicine, methodology as well as patient advocates formulated eight PICO (Patient, Intervention, Comparison, Outcome) and two narrative questions. Following the ERS standardised methodology, we conducted systematic reviews to address these questions and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to develop recommendations.The resulting guideline addresses common therapeutic options (inhalation therapy, fluticasone-azithromycin-montelukast, imatinib, ibrutinib, ruxolitinib, belumosudil, extracorporeal photopheresis and lung transplantation), as well as other aspects of general management, such as lung functional and radiological follow-up and pulmonary rehabilitation, for adults with pulmonary cGvHD phenotype bronchiolitis obliterans syndrome. These recommendations include important advancements that could be incorporated in the management of adults with pulmonary cGvHD, primarily aimed at improving and standardising treatment and improving outcomes.

show abstract

Section: Summary Of Evidencementioning

confidence: 96%

Section: Summary Of Evidencementioning

confidence: 99%

Section: Summary Of Evidencementioning

confidence: 99%

Section: Summary Of Evidencementioning

confidence: 99%

See 2 more Smart Citations

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Bos,

Murray,

Marchetti

et al. 2024

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…A review of the available literature found that most extant scholarly investigations about the QOL of LTx patients have traditionally employed aggregate scores or critical cutoff values as the primary means of assessment ( 7 , 23 ). Such an approach overlooks the intricate interplay of individual-level factors and fails to harness the rich, nuanced information embedded within each study participant.…”

Section: Introductionmentioning

confidence: 99%

Quality of life and its association with predictors in lung transplant recipients: a latent profile analysis

Song,

Luo,

Liu

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundsImproving quality of life (QOL) is one of the main aims of lung transplantation (LTx). There is a need to identify those who have poor quality of life early. However, research addressing inter individual quality of life variability among them is lacking. This study aims to identify group patterns in quality of life among lung transplant recipients and examine the predictors associated with quality of life subgroups.MethodsIn total, 173 lung transplant recipients were recruited from one hospital in Guangdong Province between September 2022 and August 2023. They were assessed using the Lung Transplant Quality of Life scale (LT-QOL), Mindful Attention Awareness Scale (MAAS), Life Orientation Test-Revised scale (LOT-R), and Positive and Negative Affect Scale (PANAS). Latent profile analysis was used to identify QOL subtypes, and logistic regression analysis was used to examine the associations between latent profiles and sociodemographic and psychosocial characteristics.ResultsTwo distinct QOL profiles were identified: “low HRQOL” profile [N = 53 (30.94%)] and “high HRQOL” profile [N = 120 (69.06%)]. Single lung transplant recipients, and patients who reported post-transplant infection, high levels of negative emotion or low levels of mindfulness and optimism were significantly correlated with the low QOL subgroup.ConclusionUsing the domains of the LT-QOL scale, two profiles were identified among the lung transplant recipients. Our findings highlighted that targeted intervention should be developed based on the characteristics of each latent class, and timely attention must be paid to patients who have undergone single lung transplantation, have had a hospital readmission due to infection, exhibit low levels of optimism, low levels of mindfulness or high negative emotions.

show abstract

Lung Transplantation for Hematopoietic Stem Cell Transplant Patients

Gadre

Benninger

2023

Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation

View full text Add to dashboard Cite

Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation

Cited by 3 publications

References 30 publications

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Quality of life and its association with predictors in lung transplant recipients: a latent profile analysis

Lung Transplantation for Hematopoietic Stem Cell Transplant Patients

Contact Info

Product

Resources

About